Natalie Mastin, Luke Durell, Bryan W Brooks, Amanda S Hering
Advancing statistical treatment of photolocomotor behavioral response study data
PloS one
expanded access programs eaps allow cancer patients unmet clinical need obtain access preauthorisation treatments standardised process implementing programs nationally realworld data impact lacking study aimed evaluate prevalence eaps impact cancer centre data relating adult cancer patients treated via eaps 2011 2021 three cork university hospitals collated descriptive statistics employed get overview impact programs currently cancer care provision identified 193 patients accessed eaps study period availing 33 separate drugs total 50 different cancer indications prevalence eap usage shown trending upwards recent years total 189 programs accessed throughout period drugs provided number different anticancer drug classes particularly targeted therapies n 18 immune checkpoint inhibitors n 17 cancers wide range solid liquid tumour types treated eap drugs patients treated across broad spectrum ages 2682 sd 1199 eaps increasing role accessing novel cancer therapies community extension nationally equity eap access would facilitated national registry available agents established assessment benefits toxicities would enhanced requirement realworld database condition eap approval